Catheter ablation for paroxysmal and persistent atrial fibrillation

被引:17
|
作者
Chen, Huai Sheng [1 ]
Wen, Jun Min [1 ]
Wu, Sheng Nan [1 ]
Liu, Jian Ping [2 ]
机构
[1] Ji Nan Univ, Affiliated Hosp 2, Shenzhen Peoples Hosp, Intens Care Unit, Shenzhen 518020, Guangdong, Peoples R China
[2] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2012年 / 04期
关键词
PULMONARY VEIN ISOLATION; QUALITY-OF-LIFE; RHYTHM-CONTROL; RADIOFREQUENCY ABLATION; ANTIARRHYTHMIC-DRUGS; RANDOMIZED-TRIAL; CIRCUMFERENTIAL ABLATION; SUBSTRATE ABLATION; DIABETES-MELLITUS; ISTHMUS ABLATION;
D O I
10.1002/14651858.CD007101.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia seen in cardiovascular departments. Treatments include medical interventions and catheter ablation. Due to uncertainties in medical therapies for AF, and the need to continue sinus rhythm, ablation has been recently considered as a viable alternative. Many new ablation methods based on pulmonary vein isolation (PVI) have been developed. Objectives The primary objective of this review was to assess the beneficial and harmful effects of catheter ablation (CA) in comparison with medical treatment in patients with paroxysmal and persistent AF. The secondary objective was to determine the best regimen of CA. Search methods Searches were run on The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library Issue 3 2009, MEDLINE (1950 to August 2009), EMBASE (1980 to August 2009), the Chinese Biomedical Literature Database (1978 to August 2009) and the CKNI Chinese Paper Database (1994 to 2009). Several journals published in Chinese were also handsearched. Selection criteria Randomised controlled trials (RCTs) in people with paroxysmal and persistent AF treated by any type of CA method. Two reviewers independently selected the trials for inclusion. Data collection and analysis Assessments of risk of bias were performed by two reviewers, and relative risk (RR) and 95% confidence intervals (CI) were used for dichotomous variables. Meta-analysis were performed where appropriate. Main results A total of 32 RCTs (3,560 patients) were included. RCTs were small in size and of poor quality. CA compared with medical therapies: seven RCTs indicated that CA had a better effect in inhibiting recurrence of AF [RR 0.27; 95% CI 0.18, 0.41)] but there was significant heterogeneity. There was limited evidence to suggest that sinus rhythm was restored during CA (one small trial: RR 0.28, 95% CI 0.20-0.40), and at the end of follow-up (RR 1.87, 95% CI 1.31-2.67; I-2=83%). There were no differences in mortality (RR, 0.50, 95% CI 0.04 to 5.65), fatal and non-fatal embolic complication (RR 1.01, 95% CI 0.18 to 5.68) or death from thrombo-embolic events (RR 3.04, 95% CI 0.13 to 73.43). Comparisons of different CAs; 25 RCTs compared CA of various kinds. Circumferential pulmonary vein ablation was better than segmental pulmonary vein ablation in improving symptoms of AF (p<=0.01) and in reducing the recurrence of AF (p<0.01). There is limited evidence to suggest which ablation method was the best. Authors' conclusions There is limited evidence to suggest that CA may be a better treatment option compared to medical therapies in the management of persistent AF. This review was also unable to recommend the best CA method.
引用
收藏
页数:73
相关论文
共 50 条
  • [31] Catheter Ablation of Lone Atrial Fibrillation
    Mujovic, Nebojsa M.
    Marinkovic, Milan M.
    Potpara, Tatjana S.
    Geller, Laszlo
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (05) : 591 - 612
  • [32] The 2020 ESC atrial fibrillation guidelines for atrial fibrillation catheter ablation, CABANA, and EAST
    Arbelo, Elena
    Dagres, Nikolaos
    EUROPACE, 2022, 24 (SUPPL 2): : 3 - 7
  • [33] Safety and efficacy of the nMARQ catheter for paroxysmal and persistent atrial fibrillation
    Vurma, Martin
    Dang, Lam
    Brunner-La Rocca, Hans-Peter
    Sutsch, Gabor
    Attenhofer-Jost, Christine H.
    Duru, Firat
    Scharf, Christoph
    EUROPACE, 2016, 18 (08): : 1164 - 1169
  • [34] Cost-effectiveness of atrial fibrillation catheter ablation
    Andrikopoulos, George
    Tzeis, Stylianos
    Maniadakis, Nikos
    Mavrakis, Hercules E.
    Vardas, Panos E.
    EUROPACE, 2009, 11 (02): : 147 - 151
  • [35] Cost-effectiveness of catheter ablation for atrial fibrillation
    Khaykin, Yaariv
    CURRENT OPINION IN CARDIOLOGY, 2007, 22 (01) : 11 - 17
  • [36] Ablation Therapy for Persistent Atrial Fibrillation
    Ifedili, Ikechukwu
    Mouksian, Kristina
    Jones, David
    El Masri, Ibrahim
    Heckle, Mark
    Jefferies, John
    Levine, Yehoshua C.
    CURRENT CARDIOLOGY REVIEWS, 2022, 18 (02) : 40 - 46
  • [37] Pearls and Pitfalls in Catheter Ablation of Persistent Atrial Fibrillation
    Lo, Li-Wei
    Lin, Yenn-Jiang
    Chang, Shih-Lin
    Hu, Yu-Feng
    Chung, Fa-Po
    Chen, Shih-Ann
    CIRCULATION JOURNAL, 2016, 80 (02) : 306 - 313
  • [38] End points for catheter ablation of persistent atrial fibrillation
    Katritsis, Demosthenes G.
    HEART RHYTHM, 2017, 14 (04) : 484 - 485
  • [39] Impact of Catheter Ablation for Atrial Fibrillation on Quality of Life
    Rohrer, Ursula
    Manninger, Martin
    Zirlik, Andreas
    Scherr, Daniel
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
  • [40] Catheter ablation for atrial fibrillation: indications and future perspective
    Natale, Andrea
    Mohanty, Sanghamitra
    Sanders, Prashanthan
    Anter, Elad
    Shah, Ashok
    Al Mohani, Ghaliah
    Haissaguerre, Michael
    EUROPEAN HEART JOURNAL, 2024, 45 (41) : 4383 - 4398